Abstract:Host cell proteins (HCPs) are process-related impurities that are generated by the host organism and are typically present at low levels in recombinant biopharmaceutical products, such as therapeutic antibodies. While overall HCP levels are usually monitored by enzyme-linked immunosorbent assay (ELISA), liquid chromatography coupled to mass spectrometry (LC-MS) is emerging as a powerful tool that can provide both qualitative and quantitative information about HCP levels during purification process development. However, a major challenge for LC-MS-based methods is that there can be a more than 5 orders of magnitude difference in the concentration between HCPs and therapeutic antibody in solution, which precludes the effective identification of low abundance HCPs in antibody product. This work reports a simple and powerful strategy to identify HCPs in antibody drug substance by applying molecular weight cutoff (MWCO) filtration step followed by shotgun proteomic analysis. After dissociating the interaction between HCPs and antibody with an anionic detergent, the depletion of antibody from HCPs can be easily achieved with the MWCO filtration step. Using this method, we observed that the dynamic range across proteins in the HCP samples was significantly decreased up to 1000-fold. In addition, by spiking in known amounts of HCPs to purified antibody drug substance with low levels of HCPs, we demonstrated that our method could detect HCP with low molecular weight (11 kDa and 17 kDa) at a concentration as low as 1 ppm. When applying this methodology to the study of HCPs in NIST monoclonal antibody (NISTmAb), more than 150 HCPs were confidently identified, which doubles the number of identified HCPs that have been previously reported. Parallel reaction monitoring (PRM) results confirmed that the novel HCPs found using this method were present in very low abundance (0.01-8 ppm), highlighting that our method reduces the dynamic range by removing antibody interference and improving the sensitivity of HCP identification and quantification.

Effective strategies for host cell protein clearance in downstream processing of monoclonal antibodies and Fc-fusion proteins

Two major mechanisms contributing to copurification of CHO host cell proteins and strategies to minimize their negative impact

UV/Vis-based process analytical technology to improve monoclonal antibody and host cell protein separation

Host cell proteins in monoclonal antibody processing: Control, detection, and removal

Chromatographic technology in antibody purification and its progress

Identification and characterization of CHO host-cell proteins in monoclonal antibody bioprocessing

Methods for addressing host cell protein impurities in biopharmaceutical product development

Risk Control of Host Cell Proteins in One Therapeutic Antibody Produced by Concentrated Fed‐batch (CFB) Mode

Improved clearance of host cell protein impurities at the polishing purification step using multimodal chromatography

A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies

Host cell protein impurities in chromatographic polishing steps for monoclonal antibody purification

Identification and classification of host cell proteins during biopharmaceutical process development

Towards continuous mAb purification: Clearance of host cell proteins from CHO cell culture harvests via “flow‐through affinity chromatography” using peptide‐based adsorbents

Host cell protein networks as a novel co‐elution mechanism during protein A chromatography

“High‐risk” host cell proteins (HCPs): A multi‐company collaborative view

Targeted CHO cell engineering approaches can reduce HCP‐related enzymatic degradation and improve mAb product quality

Characterization of the co‐elution of host cell proteins with monoclonal antibodies during protein A purification

Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development

Improved Host Cell Protein Analysis in Monoclonal Antibody Products through Molecular Weight Cutoff Enrichment

Biomimetic affinity chromatography for antibody purification: host cell proteins binding and impurity removal

Understanding the mechanism of copurification of “difficult to remove” host cell proteins in rituximab biosimilar products